An emerging role for the anti-inflammatory cytokine interleukin-10 in dengue virus infection

Tsung-Ting Tsai¹², Yi-Jui Chuang²³, Yee-Shin Lin¹³⁴, Shu-Wen Wan³⁴, Chia-Ling Chen³⁴ and Chiou-Feng Lin¹²³⁴*

Abstract

Infection with dengue virus (DENV) causes both mild dengue fever and severe dengue diseases, such as dengue hemorrhagic fever and dengue shock syndrome. The pathogenic mechanisms for DENV are complicated, involving viral cytotoxicity, immunopathogenesis, autoimmunity, and underlying host diseases. Viral load correlates with disease severity, while the antibody-dependent enhancement of infection largely determines the secondary effects of DENV infection. Epidemiological and experimental studies have revealed an association between the plasma levels of interleukin (IL)-10, which is the master anti-inflammatory cytokine, and disease severity in patients with DENV infection. Based on current knowledge of IL-10-mediated immune regulation during infection, researchers speculate an emerging role for IL-10 in clinical disease prognosis and dengue pathogenesis. However, the regulation of dengue pathogenesis has not been fully elucidated. This review article discusses the regulation and implications of IL-10 in DENV infection. For future strategies against DENV infection, manipulating IL-10 may be an effective antiviral treatment in addition to the development of a safe dengue vaccine.

Keywords: DENV, Antibody-dependent enhancement, Infection, IL-10, Immunopathogenesis

Review

Dengue virus infection

Infection with the four serotypes of dengue virus (DENV), a mosquito-borne virus belonging to the family Flaviviridae, causes a global burden of 50 million infections per year occurring across approximately 100 countries [1].

DENV infection results in a wide range of disorders, ranging from mild dengue fever (DF) to severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which can cause death in the absence of appropriate medication [1]. Dengue patients frequently present clinical symptoms ranging from a mild fever to an incapacitating high fever with severe headache, pain behind the eyes, muscle and joint pain, and rash. However, in patients with severe DHF/DSS, potentially lethal complications include plasma leakage, severe hemorrhage, and organ failure, and these complications can affect both children and adults [1,2].

The enveloped single-stranded RNA virus of dengue virus (DENV) contains 3 structural proteins, including the envelope (E) protein, the precursor membrane (prM) protein, and the capsid protein, and 7 nonstructural (NS) proteins, including NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 in endoplasmic reticulum (ER)-derived membrane structures. The newly synthesized viral RNA is incorporated into viral proteins and assembled into immature virions within the ER lumen [3-5]. The life cycle of DENV starts with the entry of infectious virions into target cells through membrane fusion and the binding of surface receptors/co-receptors. Most DENV proteins play a crucial role in the biological functions and pathogenesis of DENV. The DENV E protein is a viral receptor for cell binding and fusion in monocytes/macrophages, dendritic cells, B cells, T cells, basophil/mast cells, endothelial cells, epithelial cells, and hepatocytes [6,7]. Several surface molecules, including heparan sulfate [8], CD14 [9], dendritic cell-specific intracellular adhesion molecule 3 grabbing nonintegrin [10], GRP78 [11], laminin receptor [12], heat shock proteins [13], mannose receptor [14], C-type lectin domain family 5 member A [15], and integrins [16], are required for cell binding and entry during DENV infection. After receptor binding,
DENV infects target cells through receptor-mediated endocytosis [7]. When the virions are internalized through endocytosis, the surface E protein is rearranged under environment acidification, leading to viral and vesicle membrane fusion and the subsequent release of viral RNA into the cytoplasm. Cytosolic NS1 and NS2A proteins control viral RNA replication complexes while NS4B modulates DENV replication via interactions with NS3 [17-20]. In addition, both soluble NS1 and membrane-bound NS1 proteins may play a role in complement activation following the binding of anti-NS antibodies [21-23]. The serum levels of soluble NS1 predict DHF progression [24]. The NS2B protein, which is a co-factor of NS3, forms a complex with NS2A/NS3 to regulate viral replication, post-translation modification, and virion assembly through multifaceted enzyme activities, including RNA helicase, RNA 5′-triphosphatase (RTPase), and RNA-stimulated nucleoside triphosphatase (NTPase) activity [25]. The NS5 protein, which is the largest and most highly conserved DENV protein, acts as an RNA-dependent RNA polymerase [26] and methyltransferase [25], and it interacts with the helicase domain of NS3, triggering its RTPase and NTPase activities [27,28] during DENV replication.

Unfortunately, no safe dengue vaccine is available, even though considerable effort has been directed toward the development of several candidate vaccines [29-31]. The biggest challenge is the lack of a clear anti-viral strategy, reflecting the multifaceted pathogenesis, including viral load; virulence; cytoxicity; the nature of the immune response; autoimmunity [32,33]; and the potential effects of underlying host diseases, such as allergies, diabetes, and hypertension [34,35].

**Dengue pathogenesis**

The pathogenesis of DENV infection is classified into several types, including viral factors, cytokine storms, host genetic factors, autoimmune, and antibody-dependent enhancement (ADE) [33,36-39]. Many reports have suggested that the viral genotypic nucleotide variation is associated with disease severity [40,41]. In addition, higher levels of plasma DENV RNA have been observed in DHF patients compared with DF patients [42,43]. More data are needed to conclusively correlate viral load with disease severity. Interferons (IFNs) are central players in the innate immune system for defense against pathogen infection. However, DENV harbors a number of virulence proteins that interfere with the IFN signaling pathway [4,44-48]. The NS2A, NS4A, and NS4B proteins contribute to immune invasion by disrupting type I IFN signaling [44,46,47]. Furthermore, NS5 inhibits IFN-α signaling by inhibiting signal transducer and activator of transcription (STAT) 2 phosphorylation [45].

In addition to viral factors, including viral load, serotype, and virulence, a number of proinflammatory and anti-inflammatory responses are generated in host cells that have been infected with DENV. While aberrant inflammatory responses have been identified in DENV-infected patients, a number of cytokines, including tumor necrosis factor (TNF) α, IFN-γ, granulocyte-macrophage colony-stimulating factor, interleukin (IL)-10, and soluble TNF-α receptors (sTNFR) I and sTNFRII, exhibit greater expression in DHF/DSS patients compared with DF patients [49-54]. The immunopathogenesis of DENV infection involves host-specific immune responses, including immune cell activation, the release of cytokines (IL-1β, IL-2, IL-6, IL-10, IL-13, IL-18, macrophage migration inhibitory factor, tumor growth factor-β, TNF, and IFNs) and chemokines (IL-8, monocyte chemoattractant protein-1, and regulated and normal T cell expressed and secreted), complement activation, the production of inflammatory mediators, and autoimmunity [6,30,32,33,38,55,56]. Recently, based on genome-wide association studies has determined that host genetic factors, including the human leukocyte antigens, antibody receptors, immune/inflammatory mediators, attachment molecules, cytokines, and other immunoregulatory factors, are associated with the pathogenesis of severe dengue [37].

During infection, antibodies against soluble NS1 may lead to the complement-mediated lysis of DENV-infected cells [23]. For DENV-induced autoimmunity, anti-DENV NS1 antibodies bind to human platelets and endothelial cells [57,58]. Numerous studies [6,59-62] have reported mechanisms of molecular mimicry in which antibodies directed against DENV NS1 cross-react with human platelets and endothelial cells and cause damage and dysfunction, which may also be associated with the clinical features of dengue disease. The C-terminus of NS1 may be responsible for cross-reactivity with endothelial cells and platelets, as demonstrated through experiments using a modified NS1 lacking cross-reactive epitopes [63]. In addition, the deletion of the C-terminus of DENV NS1 abolishes anti-NS1-mediated platelet dysfunction and associated bleeding [63]. In addition, antibodies against DENV E and prM proteins also have autoimmune potential. Monoclonal anti-E antibodies bind to coagulant factor, and anti-prM antibodies bind to host cells [64,65]. Autoimmunity might therefore be involved in DENV pathogenesis; however, the timing of autoantibody generation and generated titers associated with clinical parameters need further clarification. Furthermore, the generation of autoantibodies may cause safety concerns for vaccine development.

Humoral immunity is commonly involved in DHF/DSS pathogenesis, particularly in patients with a secondary DENV infection. ADE, a phenomenon in which
non-neutralizing antibodies cross-react with heterogeneous serotypes of DENV and facilitate their binding with Fc receptor-bearing cells, facilitates severe DHF/DSS during DENV infection [55,66-68]. The generation of antibodies against the DENV E and prM proteins is fundamental for host defense; however, such immune responses may increase the risk of developing DHF/DSS upon re-infection, primarily due to the effects of ADE. In addition to the extrinsic ADE pathway, in which the Fcy receptor directly facilitates DENV binding onto the cell surface for DENV infection/replication, an intrinsic ADE pathway induces IL-10-mediated immunosuppression [55,69]. For the intrinsic pathway, the ADE of DENV infection triggers IL-10 production through an immune complex associated with the Fc receptor to enhance the infection severity. In the presence of ADE, the Fcγ receptor can facilitate viral entry and trigger intracellular signaling. Moreover, IL-10 overproduction can enhance downstream signaling protein suppressor of cytokine signaling (SOCS) 3 expression, followed by type 1 IFN signaling suppression in the human monocyte cell line THP-1 [69,70]. However, the molecular mechanisms of host and viral regulation of IL-10 expression and the pathological role of IL-10 in DENV infection are mostly unknown. Therefore, the generation of autoimmunity and ADE may cause concerns for vaccine development and ADE may cause concerns for vaccine development.

Regulation of IL-10 production in DENV infection
In DENV-infected cells, a variety of immune mediators alter anti-viral responses and inflammatory activation [6,38]; however, the mechanisms for such responses are in need of further investigation. Increased levels of serum IL-10 may be a useful prognostic hallmark in DHF/DSS patients, as discussed above. Aberrant IL-10 expression may also be involved in DENV pathogenesis, particularly for DENV infection/replication under ADE as demonstrated in vitro [55]. However, the significance of this in vivo IL-10 expression is not known.

IL-10 is a cytokine with pleiotropic effects in immunoregulation and inflammation. IL-10 may play a role in DENV pathogenesis, reflecting an immunosuppressive function that causes IFN resistance, followed by impaired immune clearance and a persistent infectious effect for acute viral infection. Duell and colleagues [81] summarized IL-10 induction in distinct pathogens. Microbes, including protozoa, nematodes, fungi, viruses, and bacteria, regulate host cell IL-10 expression to allow persistent infection [82-84]. In Table 1, we summarize a panel of epidemiological studies from the past decade that report a positive correlation between IL-10 levels and dengue disease severity [50,85-92]. Overall, higher levels of IL-10 are detected in DHF/DSS patients compared with DF patients, and this trend is observed for infants, children, and adults. The time-kinetic analysis shows increased levels of IL-10 from the onset of fever to defervescence, and viremia primarily occurs during fever in dengue patients [50,85,93]. The relationship between IL-10 and viral replication is therefore speculated, and the possible pathogen effects may result from the IL-10-mediated inhibition of the antiviral IFN response [55]. Another study showed a late peak of IL-10 production after viremia at defervescence [90]. Maximal plasma IL-10 levels measured from the acute phase of infection correlated with the degree of plasma leakage, as determined by the pleural effusion index [50,90]. Thus, IL-10 may cause lymphocyte dysfunction through the suppression of the T cell proliferative response to mitogens, which occurs in dengue patients during the early stages of infection [85,94]. Furthermore, having a decreased number of platelets, called thrombocytopenia, has been associated with the presence of IL-10 [85,90,94]. Interestingly, serum IL-10 levels have been strongly associated with the serum levels of hepatic...
transaminases AST and ALT [91]. Moreover, the level of IL-10 is higher in secondary DENV-infected patients than in primary DENV-infected patients [95,96]. IL-10 induction is associated with severe DENV infection and is a potential biomarker for acute DENV infection [93,94]. Specifically, IL-10 expression acts as a predictive marker of death for DHF patients [86].

Several possibilities have been proposed to explain DENV-induced regulation of IL-10. IL-10 is primarily produced by monocytes/macrophages, type 2 T-helper cells, and CD4+CD25+Foxp3+ regulatory T cells, which constitute a suppressive T cell population. An early report showed that increased frequencies of CD4+CD25high regulatory T cells are present in dengue patients with acute infection [97]. Based on these findings, the ratios of regulatory/effect T cells are also increased. Furthermore, the activation of this cell population and the generation of IL-10 are normal during infection. Activated regulatory T cells may be one of the IL-10-producing cell populations in circulation. Current studies have shown that cell type specificity and host genetic polymorphisms affect IL-10 production during ADE of DENV infection [98]. Specifically, in monocytes, as previously demonstrated [69,70], IL-10 is induced only in ADE infection, but not in DENV infection alone. However, other Fcγ receptor-bearing cells, including dendritic cells, B cells, mast cells, and NK cells, may also produce IL-10 in an ADE-regulated manner. An analysis of the single nucleotide polymorphisms in the IL-10 promoter region revealed that the homozygous GCC haplotype is associated with an increased level of IL-10 [98]. However, another group showed that the IL-10 (−1082/−819/−592) ACC/ATA haplotype is associated with DHF even though this haplotype results in downregulated IL-10 [92]. Although host cell responses and genetic polymorphisms complicate IL-10 regulation, these studies do not support a strong role for IL-10 in ADE-facilitated DHF/DSS progression.

Aberrant production of IL-10 could be the result of intrinsic regulation by ADE in DENV infection [70]. IL-10 activation followed by SOCS3 expression has been demonstrated during ADE in DENV infection and is also observed in patients with DHF/DSS [69]. Following DENV infection of monocytes, IL-10 expression is induced in a time-dependent manner; notably, ADE significantly facilitates this response. This study was the first report to show that DENV and ADE directly coregulate IL-10, which is increased in severe DHF/DSS patients. To explain the effects of ADE on IL-10 upregulation, intrinsic signaling through Fcγ receptor-mediated sequential activation of splenic tyrosine kinases mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) has been suggested [55]. This potential molecular mechanism needs further exploration in the near future, particularly at the level of the transcriptional and translational regulation of IL-10.

Various transcription factors are involved in the production of IL-10 by monocytes/macrophages, including activating transcription factor 1 (ATF1), CCAAT/enhancer binding protein-β (cAMP-responsive element-binding protein (CREB)), nuclear factor-κB (NF-κB), pre-B-cell leukemia transcription factor 1, PBX-regulating protein 1, specific protein 1, and MAF [99,100]. Notably, these transcription factors are commonly regulated by MAPKs, including p38 MAPK and ERK. Recent studies [101,102] reported that inhibiting glycogen synthase kinase (GSK)-3, a multi-functional serine/threonine kinase that controls protein synthesis, cell proliferation, division, differentiation, motility, inflammation, and apoptosis, downregulates Toll-like receptor (TLR)-mediated inflammatory responses but increases IL-10 production. We recently showed that GSK-3 regulates inflammatory activation in lipopolysaccharide (LPS)-activated macrophages, partly through inhibiting IL-10 [103]. Mechanistically, GSK-3 negatively regulates CREB, a transcription factor that promotes IL-10 [101,102,104]. We recently showed the mechanisms through which IFN-γ upregulates LPS-induced nitric oxide (NO) biosynthesis in macrophages through GSK-3-mediated IL-10 inhibition [105]. In the
presence of TLR signaling, inhibiting GSK-3 can increase the phosphorylation of the transcription factor CREB. CREB activation is positively mediated by protein kinase A (PKA)-, phosphatidylinositol 3-kinase/PKB-, and PKC-mediated phosphorylation [106]. In addition to PKA, PKB, and PKC, CREB is also regulated by GSK-3β, which decreases CREB stability by phosphorylating CREB at Ser129 [107,108]. Both of these kinases act upstream of GSK-3 and inactivate GSK-3 through phosphorylation at serine residues [107,109,110]. Another study showed that the overexpression of IL-10 is mediated by GSK-3 inhibition-induced PKC and ERK activation [84]. In Leishmania infection, GSK-3 negatively regulates myeloid cell IL-10 production in a PI3K/PKB/CREB-dependent manner [111]. During ADE of DENV infection, Fcγ receptor may also trigger both ERK and PKC signaling [55]. Therefore, GSK-3 may be inactivated during DENV infection, which might be important for DEN-induced IL-10 production.

Implications of IL-10 in dengue pathogenesis
Consistent with many human viruses, such as human immunodeficiency virus, hepatitis C virus, and Epstein-Barr virus, DENV infection also induces IL-10 production [69,112-114]. In ADE infections, very early IL-10 overproduction is correlated with the suppression of anti-viral responses, indicating that the timing of IL-10 expression is important for immunosurveillance. Extrinsic ADE infection contributes to a high rate of viral infection in Fcγ receptor-bearing cells, whereas the intrinsic ADE effect via IL-10 suppresses the activation of the IFN-mediated antiviral response. For modulating the immune response, SOCS3 plays a key role downstream of IL-10 signaling [115]. Interactions between IL-10 and IL-10 receptors activate the Jak/STAT pathway, leading to downstream gene transcription that promotes the anti-inflammatory response [80,116-119]. Several reports have shown that IL-10 might suppress the immune response through negatively regulating MyD88 expression in mononuclear cells [116,120]. ADE of DENV infection may be the principal cause of IL-10-mediated immunopathogenesis. Strategies to manipulate IL-10 regulation may facilitate the development of a safe DENV vaccine, perhaps by providing a way to protect against the effects of ADE caused by current candidate vaccines.

IL-10 can block NF-κB activity, and NF-κB is critical for TLR-mediated antiviral IFN responses; pro-inflammatory activation; production of IL-2, IL-12, TNF-α, and IFN-γ; and expression of MHC class II antigens and co-stimulatory molecules [71,121]. In severe DHF/DSS patients, the levels of IL-2, IL-12, and IFN-γ are decreased [122]; however, the mechanisms underlying this decrease are still unknown. IL-10 is released to inhibit the action of antiviral NK cells during the immune response to viral infection [123,124]. This release may prolong viral infection, and inhibiting IL-10 might facilitate the antiviral response. High titers of viremia, caused by the ADE of DENV infection, determine the frequency of DHF/DSS progression [39,94,125]. In addition to the involvement of extrinsic ADE-mediated viral infection, delayed viral clearance mediated through IL-10 immunosuppression may be involved in DENV pathogenesis.

The type II T-helper cell-derived cytokine IL-10 typically attenuates the type I T-helper cell-derived IFN-γ-activated Jak/STAT signaling pathway [80,115,117-119]. IL-10-induced SOCS3 can block the interaction of STAT1 and the IFN-γ receptor to inhibit the activation of IFN-γ. IFN-γ activity is important for preventing DENV-induced mortality, as demonstrated in an experimental murine model [126]. An antiviral axis of IFN-γ-inducible NO synthase/NO-mediated control of viral replication is exhibited in host cells that have been infected with DENV. Consistent with the findings that Bordetella parapertussis-induced IL-10 limits host cytoprotective IFN-γ responses [127], aberrant IL-10 production may also be required for IFN-γ resistance during ADE of DENV infection. Notably, the ADE of DENV infection causes aberrant production of IL-10, followed by aberrant SOCS3 expression and IFN resistance [69,70]. An intrinsic pathway involving the Fcγ receptor may facilitate DENV infection/replication following IL-10-mediated blockade of antiviral IFN responses. During microbial infection, the generation of such infectious immune complexes may also cause similar IL-10-mediated immunopathogenesis [55].

![Figure 1 Theoretical model for IL-10 production and its pathogenic role during DENV infection. IL-10 is produced in T cells (T1 and Treg) through an unknown mechanism and in Fcγ receptor-bearing cells directly through viral receptors and indirectly through an ADE-facilitated manner. The extrinsic ADE pathway occurs through Fcγ receptor-facilitated virus contact and entry following viral receptor-mediated endocytosis. An alternative intrinsic ADE pathway may trigger Fcγ receptor-mediated signaling to activate Syk/PKC/ERK-regulated IL-10 expression. However, the molecular mechanisms for IL-10 production remain unclear. Crosstalk between PKC/PKA/PKB-regulated GSK-3 for the transcriptional regulation of IL-10 and the involvement of genetic factors are also summarized. IL-10-regulated SOCS3 expression may benefit DENV replication by facilitating IFN resistance.](http://www.jbiomedsci.com/content/20/1/40)
Molecular mimicry between DENV proteins and host proteins may cause autoimmunopathogenesis in DENV infection [33]. However, the mechanisms through which B cells are activated and immunotolerance is compromised remain unclear. IL-10 can enhance B cell survival, proliferation, maturation, and antibody production [128,129], implying a possible role of IL-10 for autoimmunity during DENV infection. However, it is still controversial whether IL-10 attenuates autoimmunity by blocking IFN-mediated autoimmune-associated inflammation in lupus [130]. The implication of IL-10 in DENV-induced autoimmunity needs further study.

Conclusions

IL-10 has immunomodulatory effects and is generally considered anti-inflammatory. Excessive or poorly timed IL-10 production may allow viruses to escape from immune surveillance during DENV pathogenesis. DENV-induced IL-10 production, which may be exacerbated by ADE through Fcγ receptor-mediated extrinsic and intrinsic pathways, leads to IL-10/STAT3-mediated immunosuppression and enhanced viral replication (Figure 1). The molecular basis for IL-10 induction should be investigated in cells during DENV infection and during the ADE of DENV infection. After DENV infection, the major IL-10-producing cells in the host should be identified, and the pathogenic roles of IL-10 must be clarified. In addition, the involvement of viral receptor- and Fcγ receptor-mediated signaling is key for exploring the regulation of IL-10. Targeting IL-10 regulation and signaling pharmacologically using neutralizing antibodies, antagonists, and inhibitors may represent a viable therapeutic strategy for combating the progression of severe dengue diseases.

Abbreviations

ADE: Antibody-dependent enhancement; CREB: cAMP-responsive element-binding protein; DF: Dengue fever; DHF: Dengue hemorrhagic fever; DSS: Dengue shock syndrome; DENV: Dengue virus; E: Envelope protein; ERK: Extracellular signal-regulated kinase; GSK: Glycogen synthase kinase; GM-CSF: Granulocyte-macrophage colony-stimulating factor; IFN: Interferon; IL: Interleukin; LPS: Lipopolysaccharide; MAPK: Mitogen-activated protein kinase; NO: Nitric oxide; NS: Nonstructural; NFκB: Nuclear factor-kB; NTase: Nucleoside triphosphatases; prM: Precursor membrane; PKA: Protein kinase A; RTPase: RNA 5′-triphosphatase; STAT: Signal transducer and activator of transcription; TNFR: Soluble TNF-α receptor; SOCS: Suppressor of cytokine signaling; TLR: Toll-like receptor; TNF: Tumor necrosis factor.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

TTT, YJC, YSL, SWW, FCC, and CLF designed the concept, collected information, and prepared the manuscript and figures. TTT, YJC, and CFL wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We apologize to colleagues whose relevant contributions were not cited due to space limitations. This work was supported by grants from the National Health Research Institutes (NHRI-EX101-9917NC) and the National Science Council (NSC101-2321-B-006-029), Taiwan.

Author details

1 Institute of Clinical Medicine, National Cheng Kung University, Tainan 701, Taiwan. 2 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.

References

1. Diaz-Quijano FA: Dengue. N Engl J Med 2012, 367:180. author reply 181.
2. Alexander N, Balmaseda A, Coelho IC, Dimaano E, Hien TT, Hung NT, Janisch T, Kroeber A, Lum LC, Martinez E, et al: Multicentre prospective study on dengue classification in four South-east Asian and three Latin American countries. Trop med int health TM IH 2011, 16:936–948.
3. Guzman MG, Halstead SB, Atomb H, Bucy P, Farrar J, Gubler DJ, Hunsperger E, Kroeber A, Margolis HS, Martinez E, et al: Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8:S7–S16.
4. Morrison J, Aguiri S, Fernandez-Sesmas A: Innate immunity evasion by Dengue virus. Viruses 2012, 4:397–413.
5. Perera R, Kuhn RJ: Structural proteomics of dengue virus. Curr Opin Struct Biol 2008, 18:369–377.
6. Clyde K, Kyle JL, Harris E: Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006, 80:11418–11431.
7. Rodenhus-Zybert IA, Wilshut J, Smit JM: Dengue virus life cycle: viral and host factors modulating infectivity. Cell mol life sci CMLS 2010, 67:2773–2786.
8. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM: Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nature med 1997, 3:866–871.
9. Chen YC, Wang SY, King CC: Bacterial lipopoly saccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a CD14-dependent mechanism. J Virol 1999, 73:2650–2657.
10. Tassinareitthep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller MA, Pattanapanyasat K, Sarasonbath S, Bin DL, et al: DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J exp med 2003, 197:823–829.
11. Jindadarmongwech S, Theppant C, Smith DR: Identification of GPR 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Arch Virol 2004, 149:915–927.
12. Theppant C, Smith DR: Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol 2004, 78:14927–14937.
13. Reyes-Del Valle J, Chavez-Salinas S, Medina F, Del Angel RM: Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol 2003, 77:4557–4567.
14. Miller JL, de Wet BJ, Martinez-Porelares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S: The mannose receptor mediates dengue virus infection of human dendritic cells. J Cell Biol 2005, 168:1.
15. Reyes-Del Valle J, Chavez-Salinas S, Medina F, Del Angel RM: Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol 2003, 77:4557–4567.
16. Wan SW, Lin CF, Lu YT, Lei HY, Anderson R, Lin YS: Endothelial cell surface expression of protein disulfide isomerase activates beta1 and beta3 integrins and facilitates dengue virus infection. J Cell Biolchem 2012, 113:1681–1691.
17. Falgout B, Chanock R, Lai CJ: Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a. J Virol 1989, 63:1852–1860.
18. Kaniyav T, Pattanakitsakul SN, Sinchailk S, Chen ST, Thongboonkerd V: Vimentin interacts with heterogeneous nuclear ribonucleoproteins and dengue nonstructural protein 1 and is important for viral replication and release. Mol Biosyst 2010, 6:793–806.
19. Lindenbach BD, Rice CM. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J Virol 1999, 73:4611–4621.
20. Umareddy I, Chao A, Sampath A, Gu F, Vasudevan SG. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J Gen Virol 2006, 87:2605–2614.
21. Falleri WA, Jr, Dewan AR, Halstead SB. Human antibody to dengue soluble complement-fixing (SCF) antigens. J Immunol 1973, 111:1804–1809.
22. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Puttikhunt C, et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193:1078–1088.
23. Avirutnan P, Hautha RE, Somnukke P, Blom AM, Diamond MS, Atkinson JP. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol 2011, 187:424–433.
24. Pawitan JA. Dengue virus infection: predictors for severe dengue. Acta medica Indonesiaana 2011, 43:129–135.
25. Banerjee D, Eglolf MP, Mulard L, Guerrero C, Romette JL, Canard B. A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′-triphosphate. J Biol Chem 2004, 279:35636–35643.
26. Tan BH, Fu J, Sugrie RJ, Yap EH, Chan YC, Tan YH. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology. 1996, 216:317–325.
27. Kapoor M, Zhang L, Ramachandra M, Kusukawa J, Ebner KE, Padmanabhan C, et al. Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Arch Virol 2011, 156:2023–2032.
28. Simons CP, Farrar JJ, Nguyen V, Wills B: Dengue virus infection: predictors for severe dengue. Curr Opin Infect Dis 2011, 24:422–427.
29. Murphy BR, Whitehead SS. Autoimmunity in dengue pathogenesis. J Infect Dis 2000, 182:824.
30. Tuiskunen A, Monteil V, Plumet S, Boubis L, Wahlstrom M, Duong V, Buchy P, Lundkvist A, Tolou H, Leparc-Goffart I. Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Arch Virol 2011, 156:2023–2032.
31. Fadlou TI, Ziyin J, Ichiko H, Green S, Vaughn DW, Kalayanarooj S, Nisalak A, Norman JE, Ennis FA, Rothman AL: Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction. J Med Virol 2001, 63:29–34.
32. Yang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, Lin SC, Ho ST, Huang JH, King CC: High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology 2003, 305:330–338.
33. Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 2005, 79:5414–5420.
34. Shane E, Ennis FA: Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193:1078–1088.
35. Piray MJ, Rawlinson SM, Butcher RE, Barton CL, Waterhouse TA, Vasudevan SG, Bordin PG, Wright PJ, Jans DA, Davidson AD: Nuclear localization of dengue virus nonstructural protein 5 through its importin alpha/beta-recognized nuclear localization sequences is integral to viral infection. Traffic 2007, 8:795–807.
36. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587–619.
37. Simmons CP, Farrar JJ, Nguyen V, Wills B: Dengue. N Engl J Med 2012, 366:1423–1432.
38. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011, 24:442–450.
39. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
40. Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, Ping L, Anderson P, Reh Y, Lin YS. Autoimmunity in dengue pathogenesis. J Formosan Med Assoc = Tzu hui yu zh 2011, 110:323–11.
41. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
42. Figueiredo MA, Rodrigues LG, Barreto ML, Kornoti C, Infant A, Predmanabhan R: Association between NS3 and NS5 proteins of dengue virus type 2 and the putative RNA replicase is linked to differential phosphorylation of NS5. J Biol Chem 1995, 270:19100–19106.
43. Phyo PY, Rawlinson SM, Butcher RE, Barton CL, Waterhouse TA, Vasudevan SG, Bordin PG, Wright PJ, Jans DA, Davidson AD: Nuclear localization of dengue virus nonstructural protein 5 through its importin alpha/beta-recognized nuclear localization sequences is integral to viral infection. Traffic 2007, 8:795–807.
44. Morphus JR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587–619.
45. Norman JE, Ennis FA, Rothman AL: Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction. J Med Virol 2001, 63:29–34.
46. Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, Lin SC, Ho ST, Huang JH, King CC: High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology 2003, 305:330–338.
47. Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 2005, 79:5414–5420.
48. Shane E, Ennis FA: Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193:1078–1088.
49. Piray MJ, Rawlinson SM, Butcher RE, Barton CL, Waterhouse TA, Vasudevan SG, Bordin PG, Wright PJ, Jans DA, Davidson AD: Nuclear localization of dengue virus nonstructural protein 5 through its importin alpha/beta-recognized nuclear localization sequences is integral to viral infection. Traffic 2007, 8:795–807.
50. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587–619.
51. Simmons CP, Farrar JJ, Nguyen V, Wills B: Dengue. N Engl J Med 2012, 366:1423–1432.
52. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011, 24:442–450.
53. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
54. Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, Ping L, Anderson P, Reh Y, Lin YS. Autoimmunity in dengue pathogenesis. J Formosan Med Assoc = Tzu hui yu zh 2011, 110:323–11.
55. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
56. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
57. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
58. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
59. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
60. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
61. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
62. Halstead SB. Controversies in dengue pathogenesis. Paediatrics in child health 2012, 32(Suppl):115–9.
1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. J Immunol 2009, 183:1797–1803.
64. Huang HY, Chang BI, Lei HY, Liu HS, Liu CC, Wu HL, Yeh TM. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Clin Exp Immunol 1997, 110:35–40.
65. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, Chen SH, Liu CC, Lei HY. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 2006, 176:2825–2832.
66. Boonmak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, Porter K, Rudiman FR, Juwono D, Puthavathana P, Moravich MA: Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 2008, 82:3939–3951.
67. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Neutralization and antibody-dependent enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Nat Acad Sci United States Am 2007, 104:9422–9427.
68. Hallstead SB: Neutralization and antibody-dependent enhancement of dengue viruses. Adv virus res 2003, 60:421–467.
69. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N: Neutralization of dengue virus 2 (DENV 2) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 2007, 88:365–375.
70. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol 2008, 180:5771–5777.
71. Wilson EB, Brooks DG: The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol 2011, 350:39–65.
72. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J exp med 1989, 170:2081–2095.
73. Jung M, Sabat R, Kratzschmar J, Seidel H, Wolk K, Schonbein C, Schutt S, Friedrich M, Docke WD, Asadullah K, Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, Cabrera MV, Rodriguez R, Rosario D, Martinez E, Denny T, Guzman MG: IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol 2004, 73:230–234.
74. Zhang F, Yuan Y, Wang HL, Wang LB: Kinesin-1 inhibits TLR4-mediated IL-1β secretion and IFN-β induction through the endosome. J Leukoc Biol 2012, 91:509–519.
75. Martin M, Rehani K, Jope RS, Michalek SM. GSK3: an in-Toll-erant protein kinase? Nat Rev Immunol 2005, 7:572–584.
76. Hu X, Paik PK, Chen J, Yarilina A, Kocakcioglu L, Lu TT, Woodgett JR, Ivashkiv LB. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB-AP-1 proteins. Immunity 2006, 24:563–574.
77. Li C, Tsai CC, Huang WC, Wang CY, Tseng HC, Wang Y, Kai JL, Wang SW, Cheng YL: IFN-gamma synergizes with LPS to induce nitric oxide
biosynthesis through glycogen synthase kinase-3-inhibited IL-10. 
J Cell Biochem 2008, 105:746–755.

106. Mayr B, Montminy M: Transcriptional regulation by the phosphorylation-dependent factor CREB. 
Nat Rev Mol Cell Biol 2001, 2:599–609.

107. Chiu CT, Chuang DW: Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. 
Pharmacol Ther 2010, 128:281–304.

108. Fiol CJ, Williams JS, Chou CH, Wang QM, Roach PJ, Andrisani OJ: 
A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. 
J Biol Chem 1994, 269:32187–32193.

109. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. 
Nature 1995, 378:785–789.

110. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB: Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. 
Proc Natl Acad Sci U S A 2000, 97:11960–11965.

111. Nandan D, Camargo De Oliveira C, Hoevenezakhlanou A, Lopez M, Silverman JM, Subek J, Reiner NE: Myeloid cell IL-10 production in response to leishmanias involves inactivation of glycogen synthase kinase-3beta downstream of phosphatidylinositol-3 kinase. 
J Immunol 2012, 188:367–378.

112. Lambert SJ, Martinez OM: Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinas to induce production of IL-10. 
J Immunol 2007, 179:8225–8234.

113. Ostrowicki MA, Gu JX, Kovacs C, Freedman J, MacDonald KS: Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag-1 infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses. 
J Infect Dis 2001, 184:1268–1278.

114. Woitas RP, Petersen U, Moshage D, Brackmann HH, Matz B, Sauerbruch T, Ostrowski MA, Gu JX, Kovacs C, Freedman J, Luscher MA, MacDonald KS: 
Phosphorylation and inactivation of glycogen synthase kinase-3 by insulin mediated by protein kinase B. 
Nature 1995, 378:785–789.

115. Yoshida T, Yokochi T: Interleukin-10 inhibits tumor necrosis factor-alpha production by monocytes in a cAMP-dependent factor CREB. 
Transcriptional regulation by the phosphorylation-depended CREB response to leishmania involves inactivation of glycogen synthase kinase-3beta downstream of phosphatidylinositol-3 kinase. 
J Immunol 2012, 188:367–378.

116. Chang J, Kunkel SL, Chang CH: Inactivation of glycogen synthase kinase-3 by insulin mediated by protein kinase B. 
Nature 1995, 378:785–789.

117. El Kasmi KC, Holst J, Coffre M, Mielke L, de Pauw A, Lhocine N, Smith AM, Rutschman R, Kaushal D, Shen Y, Garra A, J Immunol 2007, 179:8225–8234.

118. Moore KW, de Waal MR, Coffman RL, O’Garra A: Interleukin-10 and the interleukin-10 receptor. 
Annu Rev Immunol 2001, 19:683–765.

119. Murray PJ: STAT3-mediated anti-inflammatory signalling. 
Biochem Soc Trans 2006, 34:1028–1031.

120. Daguadori J, Naik Y, Tumurkhluu G, Hassan F, Islam S, Koide N, Mori I, Yoshida T, Yokochi T: Interleukin-10 inhibits tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW 264.7 cells through reduced MyD88 expression. 
Innate immunity 2008, 14:109–115.

121. Vicari AP, Trinchieri G: Interleukin-10 in viral diseases and cancer: exiting the labyrinth? 
Immunol Rev 2004, 202:223–236.

122. Chaturvedi UC, Agarwal R, Elbashbishi EA, Mustafa AS: Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. 
FEMS Immunol Med Microbiol 2000, 28:183–188.

123. Blackburn SD, Wherry EJ: IL-10: T cell exhaustion and viral persistence. Trends Microbiol 2007, 15:143–146.

124. Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB: IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. 
J exp med 2008, 205:533–541.

125. Endy TP, Nisalak A, Chunsutthawat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Librati DH: Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. 
J Infect Dis 2004, 189:990–1000.

126. Costa W, Fagundes CT, Valadao DF, Cisapino D, Dias AC, Silveira KD, Kangussu LM, Avila TV, Bonfim MR, Bonaventura D, et al: A model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-gamma in host resistance to infection. 
PLoS Negl Trop Dis 2012, 6:e1663.

127. Wolfe DN, Karamakis AT, Hester SE, Kennett MJ, Harvill ET: IL-10 induction by Bordetella parapertussis limits a protective IFN-gamma response. 
J Immunol 2010, 184:1392–1400.

128. Groux H, Cottrez F: The complex role of interleukin-10 in autoimmunity. 
J Autoimmun 2003, 20:281–285.

129. Wakkach A, Cottrez F, Groux H: Can interleukin-10 be used as a true immunoregulatory cytokine? 
Eur Cytokine Netw 2000, 11:153–160.

130. Hill N, Sarvetnick N: Cytokines: promoters and dampeners of autoimmunity. 
Curr Opin Immunol 2002, 14:791–797.